Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Prenetics Group ( (PRE) ) is now available.
On June 18, 2025, Prenetics Global Limited announced the divestment of its majority stake in ACT Genomics to Delta Electronics, a transaction valued at up to US$71.78 million. This strategic move strengthens Prenetics’ financial position, increasing its cash reserves to approximately US$86 million and short-term assets to US$117 million, while maintaining a debt-free balance sheet. The divestment aligns with Prenetics’ strategy to focus on its high-growth consumer health brands, simplifying its business model and enhancing financial flexibility. The company has raised its FY2025 revenue outlook, driven by the success of its IM8 brand, and is exploring innovative treasury management strategies, including digital assets.
The most recent analyst rating on (PRE) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
Prenetics Group’s overall score is driven primarily by its financial performance, which highlights significant profitability and cash flow challenges. The technical analysis provides some positive signals, but valuation concerns due to negative earnings weigh heavily on the stock’s attractiveness. The lack of earnings call data and notable corporate events means these factors do not influence the score.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited is a leading health sciences company focused on advancing consumer and clinical health. The company operates through its consumer health brands, including IM8, a premium health and wellness brand, CircleDNA, a direct-to-consumer DNA testing platform, and Europa, a major sports nutrition distribution company in the USA. Prenetics is committed to enhancing life through science and has a significant stake in the early cancer detection company, Insighta.
Average Trading Volume: 25,869
Technical Sentiment Signal: Buy
Current Market Cap: $91.37M
See more insights into PRE stock on TipRanks’ Stock Analysis page.